Pluristem Therapeutics, Inc. has received approval from the FDA for the comparability studies of its PLacental eXpanded (PLX) cell products and was granted approval for the manufacture these products at its new commercial-scale cell manufacturing facility. “We believe we have the largest, scalable, most efficient, most consistent and controlled process for manufacturing cell therapies,” said Zami Aberman, chairman and chief executive officer of Pluristem. “Knowing that the &#8...